Vaxcyte, Inc. financial data

Symbol
PCVX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
825 Industrial Road, Ste. 300, San Carlos, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
SutroVax, Inc. (to 4/3/2020)
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.34K % -25.1%
Debt-to-equity 7.1 % +9.92%
Return On Equity -30.1 % -4.81%
Return On Assets -28.1 % -4.19%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 112M shares +18.9%
Common Stock, Shares, Outstanding 111M shares +17.9%
Entity Public Float 4.1B USD +273%
Common Stock, Value, Issued 114K USD +17.5%
Weighted Average Number of Shares Outstanding, Basic 117M shares +19.6%
Weighted Average Number of Shares Outstanding, Diluted 117M shares +19.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 428M USD +85.9%
General and Administrative Expense 74.5M USD +47.7%
Operating Income (Loss) -577M USD -90.2%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -497M USD -87.8%
Earnings Per Share, Basic -4.69 USD/shares -39.6%
Earnings Per Share, Diluted -4.69 USD/shares -39.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 519M USD -2.33%
Other Assets, Current 1.38M USD
Assets, Current 1.48B USD +13.1%
Property, Plant and Equipment, Net 126M USD +667%
Operating Lease, Right-of-Use Asset 26.8M USD +48.7%
Other Assets, Noncurrent 52.7M USD +1415%
Assets 2.09B USD +38.9%
Accounts Payable, Current 10.5M USD -35.7%
Employee-related Liabilities, Current 6.46M USD +46.4%
Accrued Liabilities, Current 22.2M USD +15.5%
Liabilities, Current 82.8M USD +37.6%
Operating Lease, Liability, Noncurrent 18.3M USD +98.3%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 101M USD +45.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.82M USD
Retained Earnings (Accumulated Deficit) -1.15B USD -76.4%
Stockholders' Equity Attributable to Parent 1.99B USD +38.6%
Liabilities and Equity 2.09B USD +38.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -159M USD -234%
Net Cash Provided by (Used in) Financing Activities 818M USD +1869%
Net Cash Provided by (Used in) Investing Activities -451M USD -0.66%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 111M shares +17.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 214M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 520M USD -2.28%
Deferred Tax Assets, Valuation Allowance 288M USD +75.2%
Deferred Tax Assets, Gross 297M USD +74.2%
Operating Lease, Liability 25.6M USD +68.2%
Payments to Acquire Property, Plant, and Equipment 5.68M USD +1.23%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -493M USD -85%
Lessee, Operating Lease, Liability, to be Paid 32.3M USD +94.1%
Property, Plant and Equipment, Gross 138M USD +473%
Operating Lease, Liability, Current 7.29M USD +21.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.9M USD -57.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 9.84M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +13.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.75M USD +366%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.99M USD -57.5%
Deferred Tax Assets, Operating Loss Carryforwards 135M USD +21.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.45M USD +154%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.08M USD
Operating Lease, Payments 8.83M USD +35.6%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 999K USD +40.3%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%